Early Test of Cure
To determine the accuracy of SL-RNA detection in blood and cerebrospinal fluid and of neopterin quantification in cerebrospinal fluid, for assessing treatment outcome.
Passive Case Detection
To determine the diagnostic performance and cost-effectiveness of rapid diagnostic tests (RDTs) in peripheral health centres in low prevalence HAT foci and to establish diagnostic algorithms combining RDTs at point-of-care, and remote serological and/or molecular reference tests on blood impregnated filter paper.
Post Elimination Monitoring
To determine cost-effectiveness of different diagnostic algorithms of serological and molecular high-throughput tests with or without previous RDT blood screening.
This work package involves the regional HAT reference laboratories.
Welcome to our website
Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials (abbreviated as DiTECT-HAT) is a new programme funded under the European & Developing Countries Clinical Trials Partnership (EDCTP2). DiTECT-HAT seeks to validate the performance of diagnostic tools and algorithms for early and rapid diagnosis of Trypanosome brucei gambiense Human African Trypanosomiasis in 3 contexts: 1°for passive case detection (WP2); 2° for post-elimination monitoring (WP3); and 3° for assessing the therapeutic response (WP4).